Bandera Eye Care Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 1136 Main Street, Bandera, TX 78003 Phone: 830-850-0628 Fax: 830-850-0346 |
Bandera Eye Goods Optometrist Medicare: Not Enrolled in Medicare Practice Location: 264 Highway 16 South, Bandera, TX 78003 Phone: 830-796-7798 Fax: 830-796-9937 |
News Archive
YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.
The week, May 23 to May 29, is National Biomedical/Clinical Engineering Appreciation Week and celebrations across the country are recognizing the importance of this field to improving healthcare and the contributions of its practitioners.
Antibiotics prescribed by dentists may contribute to the growing problem of Clostridium difficile (C. diff), a serious and potentially deadly infection that causes severe diarrhea, suggests research presented at IDWeek 2017. And many of those antibiotics are likely unnecessary, researchers note.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
For parents of children with brain disorders or visual impairment, nights can be long and frustrating, leading to even more difficult days as exhaustion takes hold.
› Verified 5 days ago